Surgery Partners, Inc. Common Stock (SGRY) — Analysis Summary
Surgery Partners, Inc. Common Stock (SGRY) has a market cap of $2.09B with year-over-year revenue growth of +6.2%. Net margin stands at -2.4%. The stock trades at a P/E ratio of -27.5.
Key Takeaways
- Revenue changed +6.2% year-over-year
- Net margin of -2.4%
- P/E ratio of -27.5
Compared to other companies in the SERVICES-GENERAL MEDICAL & SURGICAL HOSPITALS, NEC sector, SGRY posted revenue growth of +6.2% and trades at a P/E of -27.5.
Surgery Partners, Inc. Common Stock (SGRY)
UPDATED — ET · SOURCE POLYGON
Red Flags & WarningsHigh Risk Signals
Multiple material red flags are active and deserve closer underwriting before relying on any valuation output.
Debt/EBITDA at 6.5x — highly leveraged, potential refinancing risk
Operating margin (11.8%) exceeds gross margin (0.0%) — check for other operating income or data classification issues
Surgery Partners Inc is a healthcare services company with an integrated outpatient delivery model focused on providing quality, cost-effective solutions for surgical and related ancillary care in support of both patients and physicians. It has one reportable segment: Surgical Facilities, which includes the operation of ASCs, surgical hospitals, anesthesia services, and multi-specialty physician practices, which earn revenues from contracts with patients in which the performance obligations are to provide health care services.
Sector
SERVICES-GENERAL MEDICAL & SURGICAL HOSPITALS, NEC
Employees
16,000
Headquarters
BRENTWOOD, TN
Exchange
XNAS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.